SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is experiencing a parabolic, historic rally driven by persistent AI-sector demand and widespread institutional interest that has triggered consecutive daily gains. While the community is actively debating the sustainability of this bubble-like momentum versus potential imminent exhaustion, sentiment remains sharply divided between bulls expecting further record-breaking upside and bears positioning for a violent mean reversion.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X ETF

Direxion Daily Semiconductor Bear 3X Shares

Direxion Daily Semiconductor Bear 3X Shares (SOXS) is trending as frustrated investors react to a record-breaking rally in the semiconductor sector that has left bearish positions heavily underwater. Community discourse is dominated by intense debates over volatility decay, the sustainability of the sector's parabolic growth, and tactical strategies for managing leveraged ETF risk amidst widespread calls for an imminent pullback.

Dogecoin is an open-source digital currency based on the "Doge" meme that functions as a peer-to-peer medium for fast payments and digital tipping. Unlike projects backed by corporate entities, its value is driven by a global community, and the project is managed by a decentralized group of volunteers and the non-profit Dogecoin Foundation rather than a formal company.  Originally created in 2013 by software engineers Billy Markus and Jackson Palmer as a market parody, the project held no public sale or venture capital rounds. The network operates as a fork of LuckyCoin, which itself was a fork of Litecoin, using a proof of work consensus mechanism. It employs the Scrypt algorithm to ensure the mining process remains fast and efficient, with new blocks processed every 60 seconds. A unique technical feature is its use of merged mining, allowing miners to secure Dogecoin simultaneously with other Scrypt-based networks like Litecoin.  To keep transaction fees low and the network running indefinitely, Dogecoin features an uncapped supply where new coins are added forever. In a major regulatory milestone in March 2026, a joint SEC and CFTC framework officially classified Dogecoin as a digital commodity, placing it in the same asset category as gold or oil.

Dogecoin

Dogecoin is facing renewed attention as crypto market sentiment fluctuates between bullish technical signals and community debates over potential price consolidation. Investors are actively discussing the symbol's struggle to break key resistance levels while weighing its long-term viability against other emerging meme coins.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is seeing a flurry of community discussion as the price hovers near key resistance levels, with many traders anticipating a breakout toward 80k. Sentiment is currently divided between bullish optimism driven by institutional ETF inflows and institutional buying, and caution regarding market volatility and geopolitical headlines.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is rallying as investors pile into the stock following confirmation of a significant order from Celestial AI, which was recently acquired by Marvell, fueling excitement about the company's role in the AI infrastructure supply chain. The community is actively discussing the stock's parabolic price action and its potential for a short squeeze, with many retail holders dismissing recent bearish short reports while eagerly anticipating potential partnerships with hyperscalers.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is capturing attention as community members discuss a potential breakout and speculative accumulation ahead of an upcoming industry event in Las Vegas. While some investors remain cautious, many are highlighting the project's long-term utility and recent infrastructure developments as reasons to remain positioned.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

Advanced Micro Devices is surging alongside the broader semiconductor sector, fueled by intense investor focus on the data center and CPU demand cycle that has also boosted Intel and other chip stocks. Community discussions highlight strong bullish sentiment driven by AI momentum, though many participants are debating whether the current parabolic price action and record-high RSI levels indicate a sustainable secular rally or a vulnerable, overbought bubble.

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

The community is actively discussing a potential breakout for PEPE as it struggles to maintain momentum above key resistance levels. Traders remain split between those bullish on future price discovery driven by market-wide meme sentiment and others skeptical of the asset's long-term volatility.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is currently surging and trending as a major short squeeze candidate following the FDA's decision to lift clinical holds on its key heart disease trial, a move that fundamentally de-risks its gene-editing pipeline. The community is focused on the massive short interest and the potential for a significant rally as traders weigh this regulatory win against an upcoming Phase 3 readout for its hereditary angioedema therapy.

X-Energy, Inc. operates as an energy company The firm focuses on modular nuclear reactors and fuel technology for clean energy generation. The company was founded by Kam Ghaffarian and Eben Mulder on 2009 and is headquartered in Rockville, MD.

X-Energy Inc. - Ordinary Shares- Class A

X-energy Inc

X-energy is trending following its robust Nasdaq IPO, with investors actively debating its long-term potential as an Amazon-backed nuclear play positioned at the intersection of AI-driven power demand and industrial infrastructure. The community is focused on the stock's significant debut performance, comparisons to existing nuclear peers, and the strategic implications of high institutional interest despite the company being in a pre-operational phase.

statis crypto Watchlist

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

What's Behind The Rise In Artelo Biosciences Stock?

Artelo Biosciences, Inc. (NASDAQ:ARTL) shares jumped on Monday after the company announced the publication of a peerreviewed article highlighting FABP5 as a therapeutic target for pain.read more...

Rogan’s Runners Market Ignites

The market is feeling the effect of Joe Rogan getting in President Trump’s ear and psychedelic therapeutics gaining regulatory tailwinds. Meanwhile, adjacent sectors are quietly building foundational breakthroughs. Wearables are evolving into neural interfaces, biomaterials are transitioning from lab curiosity to production reality, and oncology platforms continue their grind through clinical validation. $KBLB, $WLDS, $ARTL, $ENVB, $TOVX, $PBM, $CMND, $CMPS, $HELP,

<ul class="summary-bullets"><li>Artelo CEO Gregory D. Gorgas on Tuesday stated that the interim data in the Phase 2 trial of ART27.13 is encouraging.</li><li>Artelo added that ART27.13 is currently under investigation as an orally administered agent for the treatment of glaucoma in an externally funded Phase 2 study.</li><li>The company is also developing ART27.13 as a potential companion therapy to preserve muscle in patients undertaking GLP-1 treatment.</li></ul>Artelo Biosciences Inc. (ARTL) shares soared more than 21% in Tuesday’s pre-market trade&nbsp;before losing most of the gains to hover about 4% higher in the day’s opening trade after the company announced that it has regained compliance with Nasdaq’s listing requirements.Artelo stated that the Nasdaq sent a letter confirming the company is in compliance with the exchange’s rule requiring a minimum of $2.5 million in stockholders’ equity and another rule requiring an annual shareholders’ meeting.The company stated that, in accordance with Nasdaq’s listing rules, Artelo will be subject to a mandatory panel monitor for a period of one year from the date of this letter.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/ARTL">Artelo Biosciences</a> trended in the ‘bearish’ territory at the time of writing.<h2 class="st-heading-2">Artelo CEO Says ART27.13 Interim Data Is Encouraging</h2>Artelo CEO Gregory D. Gorgas stated on Tuesday that the interim data from the Phase 2 trial of ART27.13 is encouraging.“With this matter behind us, we remain focused on disciplined execution across our portfolio, including progressing potential partnership negotiations with ART27.13 boosted by the encouraging Phase 2 CAReS interim data suggesting its potential for mitigating or reversing the effects of cancer anorexia-cachexia syndrome,” he said.Artelo added that ART27.13 is currently under investigation as an orally administered agent for the treatment of glaucoma in an externally funded Phase 2 study.<h2 class="st-heading-2">Artelo Expands ART27.13’s Development</h2>The company announced last month that it had expanded development of ART27.13 as a potential companion therapy to preserve muscle in patients undergoing glucagon-like peptide-1 (GLP-1) receptor agonist therapy.Artelo cited observations among patients with cancer anorexia and cachexia showing improvements in lean body mass and physical activity during ART27.13’s Phase 2 trial.The company also closed an $11 million private placement of 3.2 million shares last week, which it intends to use toward the repayment of certain bridge debt and to meet other working capital requirements.<a href="https://stocktwits.com/symbol/ARTL">ARTL stock</a> is up 84% year-to-date, but down 58% over the past 12 months. The Vanguard Extended Market Index Fund ETF (VXF) is up 35% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/dow-futures-fall-ongoing-us-strikes-iran-trump-tuesday-deadline/cZJJpRQRIpL">Dow Futures Fall Over 200 Points Amid Ongoing US Strikes Against Iran, While Trump’s Tuesday Deadline Draws Closer</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, an Artelo Biosciences logo is seen displayed on a smartphone screen.

Why Is ARTL Stock Soaring Today?

Artelo stated that the Nasdaq sent a letter confirming the company is in compliance with the exchange’s rule requiring a minimum of $2.5 million in stockholders’ equity and another rule requiring an annual shareholders’ meeting.

Equity

<ul class="summary-bullets"><li>Artelo Biosciences shares gained more than 23% before the opening bell on Tuesday after the company announced the closure of its $11 million private placement of common stock.</li><li>Bullfrog AI shares soared more than 12% in Tuesday’s pre-market trade, building on the gains of 107% on Monday after the company announced an agreement with a major global pharmaceutical company.</li><li>Hitek Global shares more than doubled in Tuesday’s pre-market trade, soaring 110% as the company’s $3 million registered direct offering of Class A ordinary shares closed on Monday.</li></ul>U.S. equities were in the green in Tuesday’s pre-market trade after President Donald Trump reportedly indicated that he would be willing to end the Iran war without a complete reopening of the Strait of Hormuz.According to a report by The Wall Street Journal, President Trump told his aides about his willingness to end the war without getting Iran to reopen the strait following an assessment that this mission would result in prolonging the conflict beyond the four to six-week timeline.At the time of writing, the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF</a> (SPY), which tracks the S&amp;P 500 index, was up 0.92%; the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust ETF</a> (QQQ) rose 0.86%; and the&nbsp;<a href="https://stocktwits.com/symbol/DIA">SPDR Dow Jones Industrial Average ETF Trust</a> (DIA) gained 0.94%. Retail sentiment on Stocktwits regarding the S&amp;P 500 ETF was in the ‘extremely bearish’ territory.<h2 class="st-heading-2">Here are the top stocks making the biggest moves in Tuesday’s pre-market trade:</h2><a href="https://stocktwits.com/symbol/ARTL">Artelo Biosciences Inc. (ARTL)</a>Artelo Biosciences shares gained more than 23% before the opening bell on Tuesday after the company announced the closure of its $11 million private placement of common stock. Artelo stated that it intends to use the proceeds to repay a bridge debt and meet working capital requirements.<a href="https://stocktwits.com/symbol/ARTL">ARTL stock</a> is up 139% year-to-date.<a href="https://stocktwits.com/symbol/BFRG">Bullfrog AI Holdings Inc. (BFRG)</a>Bullfrog AI shares soared more than 12% in Tuesday’s pre-market trade, building on the gains of 107% on Monday after the company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/bfrg-stock-more-than-doubled-today-what-is-fueling-the-surge/cZERFnXRIZz">announced</a> an agreement with a major global pharmaceutical company to accelerate its drug discovery and clinical development programs.<a href="https://stocktwits.com/symbol/BFRG">BFRG stock</a> is up 19% year-to-date.<a href="https://stocktwits.com/symbol/HKIT">Hitek Global Inc. (HKIT)</a>Hitek Global shares more than doubled in Tuesday’s pre-market trade, soaring 110% as the company’s $3 million registered direct offering of Class A ordinary shares closed on Monday.<a href="https://stocktwits.com/symbol/HKIT">HKIT stock</a> is down 98% year to date.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/jerome-powell-fed-iran-war-effects-not-facing-policy-decision-yet/cZERs6iRIN9">Powell Says Fed ‘Not Really Facing’ Policy Decision Yet Amid Iran Oil Shock – Adds Central Bank Will Be ‘Mindful Of The Broader Context’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

ARTL, BFRG, HKIT Among Stocks Soaring Before The Bell — Top Pre-Market Gainers Today

U.S. equities gained in Tuesday’s pre-market trade after President Donald Trump reportedly stated that the Iran war could be ended without a full reopening of the Strait of Hormuz.

Medical Stocks To Research - March 27th

UnitedHealth Group, Artelo Biosciences, and Eli Lilly and Company are the three Medical stocks to watch today, according to MarketBeat's stock screener tool. Medical stocks are shares of publicly...

Artelo Biosciences Stock Skyrockets 205%

(RTTNews) - Shares of Artelo Biosciences, Inc. (ARTL) are skyrocketing about 205 percent on Friday morning trading despite no corporate-related announcements to influence the movement...

AI, Biotech, and Biologics Drive Big Narratives

A new wave of healthcare innovation, powered by artificial intelligence, next-generation biologics, and shifting regulatory pathways, is colliding with market dynamics to create both breakthrough potential and high-volatility trading setups. $ARTL, $TGNT, $ADMA, $RCKT, $LTRN, $GCTK

Artelo Biosciences Targets GLP-1 Boom with Muscle Preservation Strategy as Stock Eyes Squeeze Potential

Artelo Biosciences (NASDAQ:ARTL) is expanding the development pathway for its lead candidate ART27.13, positioning the compound as a potential companion therapy to GLP-1 weight-loss drugs, one of the fastest-growing segments in biopharma.

<ul><li>Artelo indicated it will defer the planned securities offering for the moment.</li><li>The company confirmed no shares were sold and may consider fundraising later.</li><li>On Thursday, Artelo said it plans to test ART27.13 for preserving muscle in GLP-1 patients.</li></ul>Artelo Biosciences, Inc. (ARTL)&nbsp; has formally requested the withdrawal of its recently effective registration statement for a planned securities offering, signaling a pause in its capital-raising efforts.On Friday, the company submitted a request under Rule 477 of the Securities Act of 1933 to withdraw its Form S-1, initially filed with the U.S. Securities and Exchange Commission on March 20 and declared effective on March 25.<h2 class="st-heading-2">Artelo Pauses Proposed Securities Offering</h2>Artelo stated that it does not plan to move forward with the proposed securities offering at this time.&nbsp;The company emphasized that no shares were issued or sold under the registration statement, and it intends to revisit capital-raising options in the future when conditions are more favorable.Following the update,&nbsp;<a href="https://stocktwits.com/symbol/ARTL">Artelo Biosciences stock</a> traded over 420% higher on Friday afternoon.&nbsp;On Stocktwits, retail sentiment around the stock changed to ‘extremely bullish’ from ‘bullish’ territory the previous day amid ‘extremely high’ message volume levels.&nbsp;Additionally, the company announced a new private placement involving the sale of more than 3.18 million shares or equivalent pre-funded warrants. The transaction is expected to finalize around March 30, and the company expects gross proceeds of approximately $11 million.<h2 class="st-heading-2">Strategic Expansion Initiative</h2>On Thursday, Artelo announced plans to explore a new application for its ART27.13 compound. The therapy targets muscle preservation in patients undergoing glucagon-like peptide-1 (GLP-1) receptor agonist treatment to address lean body mass loss.&nbsp;The initiative builds on multiple promising developments. ART27.13 demonstrated protective effects on muscle in the CAReS trial, showing increased lean body mass and enhanced physical activity in cancer anorexia and cachexia patients.Artelo Biosciences is a clinical-stage pharmaceutical company focused on treatments for cancer, pain, dermatologic, and neurological conditions.ARTL stock has gained over 170% year-to-date.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/entergy-meta-ink-agreement-to-fund-new-gas-plants-for-louisiana-ai-data-center/cZ3H5r4RImT">Entergy, Meta Ink Agreement To Fund New Gas Plants For Louisiana AI Data Center</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 Why Did ARTL Stock Skyrocket Over 420% Today? 

Artelo requested withdrawal of its Form S-1, effective March 25, and will not proceed with the planned securities offering.

Small Cap Stocks To Watch Now - March 18th

AltC Acquisition, Direxion Daily MU Bull 2X Shares, and Artelo Biosciences are the three Small Cap stocks to watch today, according to MarketBeat's stock screener tool. Small-cap stocks are shares of...

Artelo Biosciences, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system. Its product candidate pipeline includes ART27.13-Synthetic Cannabinoid Agonist, ART26.12-FABP5 inhibitor, and ART12.11-Synthetic CBD Cocrystal. The company was founded on May 2, 2011 and is headquartered in Solana Beach, CA.

ARTL
Artelo Biosciences Inc

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest ARTL News

ARTLArtelo Biosciences Inc